Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 4 de 4
Filter
Add more filters










Database
Language
Publication year range
1.
EMBO J ; 33(16): 1784-801, 2014 Aug 18.
Article in English | MEDLINE | ID: mdl-24975362

ABSTRACT

Mitogen-activated protein kinases (MAPKs) are highly conserved protein kinase modules, and they control fundamental cellular processes. While the activation of MAPKs has been well studied, little is known on the mechanisms driving their inactivation. Here we uncover a role for ubiquitination in the inactivation of a MAPK module. Extracellular-signal-regulated kinase 5 (ERK5) is a unique, conserved member of the MAPK family and is activated in response to various stimuli through a three-tier cascade constituting MEK5 and MEKK2/3. We reveal an unexpected role for Inhibitors of Apoptosis Proteins (IAPs) in the inactivation of ERK5 pathway in a bimodal manner involving direct interaction and ubiquitination. XIAP directly interacts with MEKK2/3 and competes with PB1 domain-mediated binding to MEK5. XIAP and cIAP1 conjugate predominantly K63-linked ubiquitin chains to MEKK2 and MEKK3 which directly impede MEK5-ERK5 interaction in a trimeric complex leading to ERK5 inactivation. Consistently, loss of XIAP or cIAP1 by various strategies leads to hyperactivation of ERK5 in normal and tumorigenic cells. Loss of XIAP promotes differentiation of human primary skeletal myoblasts to myocytes in a MEKK2/3-ERK5-dependent manner. Our results reveal a novel, obligatory role for IAPs and ubiquitination in the physical and functional disassembly of ERK5-MAPK module and human muscle cell differentiation.


Subject(s)
Inhibitor of Apoptosis Proteins/metabolism , MAP Kinase Kinase 5/metabolism , MAP Kinase Kinase Kinase 3/metabolism , MAP Kinase Kinase Kinases/metabolism , Mitogen-Activated Protein Kinase 7/metabolism , Ubiquitin/metabolism , X-Linked Inhibitor of Apoptosis Protein/metabolism , Cell Differentiation , Cells, Cultured , DNA-Binding Proteins , Enzyme Activation , Humans , Inhibitor of Apoptosis Proteins/genetics , MAP Kinase Kinase 5/genetics , MAP Kinase Kinase Kinase 2 , MAP Kinase Kinase Kinase 3/genetics , MAP Kinase Kinase Kinases/genetics , MEF2 Transcription Factors/metabolism , Mitogen-Activated Protein Kinase 7/genetics , Myoblasts/cytology , Myoblasts/metabolism , Nuclear Proteins/metabolism , Protein Multimerization , Protein Structure, Tertiary , Signal Transduction/physiology , Transcription Factors/metabolism , Ubiquitination , X-Linked Inhibitor of Apoptosis Protein/genetics
2.
EMBO J ; 31(11): 2615-28, 2012 May 30.
Article in English | MEDLINE | ID: mdl-22531785

ABSTRACT

Bacterial pathogens modulate host cell apoptosis to establish a successful infection. Pore-forming toxins (PFTs) secreted by pathogenic bacteria are major virulence factors and have been shown to induce various forms of cell death in infected cells. Here we demonstrate that the highly conserved caspase-2 is required for PFT-mediated apoptosis. Despite being the second mammalian caspase to be identified, the role of caspase-2 during apoptosis remains enigmatic. We show that caspase-2 functions as an initiator caspase during Staphylococcus aureus α-toxin- and Aeromonas aerolysin-mediated apoptosis in epithelial cells. Downregulation of caspase-2 leads to a strong inhibition of PFT-mediated apoptosis. Activation of caspase-2 is PIDDosome-independent, and endogenous caspase-2 is recruited to a high-molecular-weight complex in α-toxin-treated cells. Interestingly, prevention of PFT-induced potassium efflux inhibits the formation of caspase-2 complex, leading to its inactivation, thus resisting apoptosis. These results revealed a thus far unknown, obligatory role for caspase-2 as an initiator caspase during PFT-mediated apoptosis.


Subject(s)
Apoptosis/physiology , Caspase 2/metabolism , Cysteine Endopeptidases/metabolism , Apoptosis/drug effects , Bacterial Toxins/pharmacology , Down-Regulation , HeLa Cells , Hemolysin Proteins/pharmacology , Humans , Keratinocytes/metabolism , Pore Forming Cytotoxic Proteins/pharmacology , Potassium/analysis , Potassium/metabolism
3.
J Biol Chem ; 282(44): 31928-36, 2007 Nov 02.
Article in English | MEDLINE | ID: mdl-17804416

ABSTRACT

The putative selectivity filter of the epithelial sodium channel (ENaC) comprises a three-residue sequence G/SXS, but it remains uncertain whether the backbone atoms of this sequence or whether their side chains are lining the pore. It has been reported that the S589C mutation in the selectivity filter of alphaENaC renders the channel sensitive to block by externally applied Cd2+; this was interpreted as evidence for Cd2+ coordination with the thiol group of the side chain of alpha589C, pointing toward the pore lumen. Because the alphaS589C mutation alters the monovalent to divalent cation selectivity ratio of ENaC and because internally applied Cd2+ blocks wild-type ENaC with high affinity, we hypothesized that the inhibition of alphaS589C ENaC by Cd2+ results rather from the coordination of this cation with native cysteine residues located in the internal pore of ENaC. We show here that Cd2+ inhibits not only ENaC alphaS589C and alphaS589D but also alphaS589N mutants and that Ca2+ weakly interacts with the S589D mutant. The block of alphaS589C, -D, and -N mutants is characterized by a slow on-rate, is nearly irreversible, is voltage-dependent, and can be prevented by amiloride. The C546S mutation in the second transmembrane helix of gamma subunit in the background of the ENaC alphaS589C, -D, or -N mutants reduces the sensitivity to block by Cd2+ and renders the block rapidly reversible. We conclude therefore that the block by Cd2+ of the alphaS589C, -D, and -N mutants results from the trapping of Cd2+ ions in the internal pore of the channel and involves Cys-546 in the second transmembrane helix of the gammaENaC subunit.


Subject(s)
Cadmium/pharmacology , Epithelial Sodium Channel Blockers , Xenopus Proteins/antagonists & inhibitors , Amino Acid Sequence , Amino Acid Substitution , Animals , Epithelial Sodium Channels/chemistry , Epithelial Sodium Channels/genetics , Molecular Sequence Data , Mutagenesis, Site-Directed , Oocytes , Protein Structure, Secondary , Sequence Alignment , Xenopus Proteins/chemistry , Xenopus Proteins/genetics , Xenopus laevis
4.
Mol Pharmacol ; 71(2): 473-82, 2007 Feb.
Article in English | MEDLINE | ID: mdl-17105867

ABSTRACT

Aldosterone binds to the mineralocorticoid receptor (MR) and exerts fine control over Na+ absorption in renal collecting duct cells (CCDs). Many natural and synthetic steroids can also bind to the MR to produce agonist or antagonist effects. Here, we investigate whether androgenic hormones act as MR agonist or antagonist ligands in CCDs. Testosterone (T), dihydrotestosterone (DHT), and methyltrienolone (R1881), a synthetic androgen agonist, all bind to the MR. R1881 displayed the same affinity for MR as aldosterone. Androgens did not activate the MR transiently expressed in human embryonic kidney 293T cells but did antagonize aldosterone-induced MR trans-activation activity (R1881>DHT>T). Short-circuit current (Isc) experiments, used to measure transepithelial Na+ transport, revealed that 10(-5) M T and DHT or R1881 prevented the increase in the amiloride-sensitive component of Isc caused by aldosterone in mouse mpkCCDcl4 collecting duct cells partially and totally, respectively. In contrast, androgens had no effect on stimulated Isc elicited by the specific glucocorticoid agonist 11beta,17beta-dihydroxy-17alpha-(1-propynyl) and rost-1,4,6-trien-3-one (RU26988). Docking of steroids within the crystal structure of the ligand-binding domain of MR, together with trans-activation studies, revealed that the contacts between the 17beta-hydroxyl group of androgens and the Asn770, Cys942, and Thr945 residues of the ligand-binding cavity stabilize ligand binding complexes but are not strong enough to keep the receptor in its active state. Altogether, these findings indicate that androgen ligands, particularly R1881, act as MR antagonists in aldosterone target cells and provide new insights into the requirements for MR activation to occur and for the designing of new selective MR antagonists.


Subject(s)
Metribolone/pharmacology , Mineralocorticoid Receptor Antagonists , Androgens/pharmacology , Animals , Binding Sites , Cell Line , Electrophysiology , Humans , Kidney/cytology , Ligands , Mice , Sodium/metabolism , Testosterone Congeners/pharmacology
SELECTION OF CITATIONS
SEARCH DETAIL
...